We can study ultrarare tumors effectively in this day and age, it just takes a cooperative approach: The role of dasatinib in assorted indolent sarcomas.

about

We can study ultrarare tumors effectively in this day and age, it just takes a cooperative approach: The role of dasatinib in assorted indolent sarcomas.

Item

http://www.wikidata.org/entity/Q42333740

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

We can study ultrarare tumors ...... in assorted indolent sarcomas.

@en

We can study ultrarare tumors ...... in assorted indolent sarcomas.

@nl

type

Item

label

We can study ultrarare tumors ...... in assorted indolent sarcomas.

@en

We can study ultrarare tumors ...... in assorted indolent sarcomas.

@nl

prefLabel

We can study ultrarare tumors ...... in assorted indolent sarcomas.

@en

We can study ultrarare tumors ...... in assorted indolent sarcomas.

@nl

P1476

We can study ultrarare tumors ...... in assorted indolent sarcomas.

@en

P2093

Anthony D Elias

http://www.w3.org/2001/XMLSchema#string

Brianna Hoffner

http://www.w3.org/2001/XMLSchema#string

Victor M Villalobos

http://www.w3.org/2001/XMLSchema#string

P2860

The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25

Phase II study of imatinib in advanced chordoma.

Phase II study on lapatinib in advanced EGFR-positive chordoma.

Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)

Imatinib in advanced chordoma: A retrospective case series analysis.

The molecular aspects of chordoma.

Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor.

Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.

Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing.

P304

20-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1002/CNCR.30377

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27696384

http://www.w3.org/2001/XMLSchema#string

P932

5215314

http://www.w3.org/2001/XMLSchema#string